Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Quality of Life in Diabetic Chronic Heart Failure
NCT06706791Phase 4Recruiting
- Sponsor
- Fazaia Ruth Pfau Medical College
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic heart failure (CHF) comparing Empagliflozin Group with Placebo Group (2 arms). Primary endpoint: Kansas City Cardiomyopathy Questionnaire at 18 months. Started Apr 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT06706791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706791.